SC 101c

Drug Profile

SC 101c

Alternative Names: Epakex; SC101C

Latest Information Update: 22 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 22 Jan 2002 Discontinued-II for Cachexia in United Kingdom (Unknown route)
  • 29 Oct 1999 Profile reviewed, but no significant modifications made
  • 23 Dec 1996 Phase-II clinical trials for Cachexia in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top